Evidence map›Paper›PMID 25922840›Full record

Trial reportBioMed research international2015

Diagnostic Value of Subjective Memory Complaints Assessed with a Single Item in Dominantly Inherited Alzheimer's Disease: Results of the DIAN Study.

Christoph Laske, Hamid R Sohrabi, Mateusz S Jasielec, Stephan Müller, Niklas K Koehler, Susanne Gräber, Stefan Förster, Alexander Drzezga, Felix Mueller-Sarnowski, Adrian Danek and 7 more

Abstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Christoph LaskeGerman Center for Neurodegenerative Diseases (DZNE), 72076 Tübingen, Germany ; Section for Dementia Research, Department of Cellular Neurology, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, 72076 Tübingen, Germany ; Department of Psychiatry and Psychotherapy, University of Tübingen, 72076 Tübingen, Germany.
Hamid R SohrabiCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Perth, WA 6027, Australia ; School of Psychiatry and Clinical Neurosciences, University of Western Australia, Nedlands, WA 6009, Australia.
Mateusz S JasielecDivision of Biostatistics, Washington University School of Medicine, St. Louis, MO 63108, USA.
Stephan MüllerDepartment of Psychiatry and Psychotherapy, University of Tübingen, 72076 Tübingen, Germany.
Niklas K KoehlerDepartment of Psychiatry and Psychotherapy, University of Tübingen, 72076 Tübingen, Germany.
Susanne GräberGerman Center for Neurodegenerative Diseases (DZNE), 72076 Tübingen, Germany ; Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany.
Stefan FörsterDepartment of Nuclear Medicine & TUM Neuroimaging Center (TUM-NIC), Klinikum Rechts der Isar, Technical University Munich, 80333 Munich, Germany.
Alexander DrzezgaDepartment of Nuclear Medicine, University of Cologne, 50937 Cologne, Germany.
Felix Mueller-SarnowskiDeutsches Zentrum für Neurodegenerative Erkrankungen, 81377 München, Germany ; Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, 81377 München, Germany.
Adrian DanekDeutsches Zentrum für Neurodegenerative Erkrankungen, 81377 München, Germany ; Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, 81377 München, Germany.
Mathias JuckerGerman Center for Neurodegenerative Diseases (DZNE), 72076 Tübingen, Germany ; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany.
Randall J BatemanDepartment of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63108, USA.
Virginia BucklesDepartment of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63108, USA.
Andrew J SaykinIndiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Ralph N MartinsCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Perth, WA 6027, Australia ; School of Psychiatry and Clinical Neurosciences, University of Western Australia, Nedlands, WA 6009, Australia.
John C MorrisDepartment of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63108, USA.
Dominantly Inherited Alzheimer Network DianDepartment of Neurology, Washington University in St. Louis, MO 63108, USA.

Funding

Dominantly Inherited Alzheimer NetworkU19AG032438 · NIA · WASHINGTON UNIVERSITY · 2023 to 2025
$19.6M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · WASHINGTON UNIVERSITY · 1985 to 2005
$16.3M
PREDICTING COGNITIVE DECLINE IN NONDEMENTED ELDER SUBJECTSP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2023
$14.7M
Tau Burden and Spatial Spread in Preclinical Alzheimer DiseaseP01AG026276 · WASHINGTON UNIVERSITY · 2005 to 2025
$5.2M
NCATS NIH HHS UL1 TR001108NIA NIH HHS P01 AG003991NIA NIH HHS P01AG003991NIA NIH HHS P01AG026276NIA NIH HHS P50 AG005681NIA NIH HHS P50AG005681NIA NIH HHS U01 AG032438NIA NIH HHS U19 AG032438
6 · The paper itself

Abstract

objectiveWe examined the diagnostic value of subjective memory complaints (SMCs) assessed with a single item in a large cross-sectional cohort consisting of families with autosomal dominant Alzheimer's disease (ADAD) participating in the Dominantly Inherited Alzheimer Network (DIAN).

methodsThe baseline sample of 183 mutation carriers (MCs) and 117 noncarriers (NCs) was divided according to Clinical Dementia Rating (CDR) scale into preclinical (CDR 0; MCs: n = 107; NCs: n = 109), early symptomatic (CDR 0.5; MCs: n = 48; NCs: n = 8), and dementia stage (CDR ≥ 1; MCs: n = 28; NCs: n = 0). These groups were subdivided by the presence or absence of SMCs.

resultsAt CDR 0, SMCs were present in 12.1% of MCs and 9.2% of NCs (P = 0.6). At CDR 0.5, SMCs were present in 66.7% of MCs and 62.5% of NCs (P = 1.0). At CDR ≥ 1, SMCs were present in 96.4% of MCs. SMCs in MCs were significantly associated with CDR, logical memory scores, Geriatric Depression Scale, education, and estimated years to onset.

conclusionsThe present study shows that SMCs assessed by a single-item scale have no diagnostic value to identify preclinical ADAD in asymptomatic individuals. These results demonstrate the need of further improvement of SMC measures that should be examined in large clinical trials.

Indexed as

Alzheimer DiseaseGenetic Diseases, InbornMemoryMutationAdultFemaleHumansMaleMiddle Aged

Identifiers

PMID25922840
PMCPMC4398930

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.